Cardiology · Medical Literature
Bridging the Troponin Blind Window via the miAMI Standard: A Systematic Review and Meta-Analysis of the Circulating MicroRNA-208 Family.
Abstract
Background and Objectives: Early diagnosis of acute myocardial infarction (AMI) remains challenging due to the "diagnostic blind window" of conventional protein biomarkers and the limited sensitivity of electrocardiograms in non ST-segment elevation myocardial infarction (NSTEMI). Cardiospecific circulating microRNAs, specifically the microRNA-208 (miR-208) family, have emerged as promising candidates to bridge this gap. This systematic review and meta-analysis evaluated the diagnostic accuracy of circulating miR-208 and outlines a proposed conceptual framework to guide its clinical translation. Materials and Methods: PubMed and Embase were systematically searched up to June 24th, 2026, for clinical studies evaluating the diagnostic performance of circulating miR-208a and/or miR-208b against standard reference definitions for AMI. Risk-of-bias assessment using the QUADAS-2 tool was performed independently by two reviewers. Pooled sensitivity and specificity were estimated using bivariate random effects modeling, and sources of heterogeneity were explored via subgroup analyses. Results: Forty-one studies enrolling 6306 participants were included in the qualitative synthesis, of which 14 were eligible for meta-analysis. The pooled sensitivity and specificity of circulating miR-208 for AMI detection were 0.89 (95% CI: 0.81-0.94) and 0.90 (95% CI: 0.83-0.94), respectively. Marked between-study heterogeneity was observed. Subgroup analyses revealed significantly higher diagnostic accuracy in isolated STEMI (sensitivity: 0.95) or NSTEMI (sensitivity: 0.93) cohorts compared to mixed chest pain populations (sensitivity: 0.65; p < 0.0001). Specificity dropped from 0.90 with healthy controls to 0.80 when using non-AMI controls (p = 0.002), indicating spectrum bias. Funnel plots suggested prominent small-study effects. Conclusions: Circulating miR-208 exhibits a powerful biological signal for the early detection of cardiomyocyte injury, but its standalone clinical utility is constrained by methodological heterogeneity and publication bias. Rather than an immediate clinical tool, future prospective translation requires evaluating this biomarker within the standardized miAMI framework-conceptually prioritizing future investigation of the hyper-acute (<2 h) window, absolute quantification to resolve normalization variability, and integration into multi-marker point-of-care panels.
Clinical relevance
Acute MI diagnosis is critically hampered by the 'troponin blind window' in the first 1–2 hours after symptom onset, and by the limited ECG sensitivity in NSTEMI — leaving a high-risk patient population without a reliable early rule-in tool. Cardiospecific circulating miR-208a and miR-208b, encoded exclusively in cardiac myosin heavy-chain genes, represent mechanistically sound candidates to detect cardiomyocyte injury before troponin rises are detectable. This systematic review and meta-analysis of 41 studies (n = 6,306) provides the most comprehensive pooled diagnostic accuracy estimate to date and introduces a translational framework (miAMI) to guide rigorous clinical development of this biomarker class.
Key findings
1. Pooled sensitivity of circulating miR-208 for AMI detection was 0.89 (95% CI: 0.81–0.94) and pooled specificity was 0.90 (95% CI: 0.83–0.94), derived from a bivariate random-effects model across 14 meta-analytically eligible studies. 2. Diagnostic accuracy was substantially higher in phenotypically homogeneous cohorts: sensitivity reached 0.95 in isolated STEMI populations and 0.93 in isolated NSTEMI populations, versus only 0.65 in mixed chest pain populations (p < 0.0001), demonstrating a clinically significant spectrum effect. 3. Specificity was meaningfully reduced when comparators were non-AMI cardiac or symptomatic controls (specificity 0.80) relative to healthy controls (specificity 0.90; p = 0.002), indicating spectrum bias and raising concern about discriminative performance in the real-world chest pain pathway where competing diagnoses are prevalent. 4. Forty-one studies enrolling 6,306 participants were included in qualitative synthesis, reflecting a growing but methodologically heterogeneous evidence base; marked between-study heterogeneity was observed across pooled estimates. 5. Funnel plot asymmetry indicated prominent small-study effects, raising concern for publication bias and likely overestimation of pooled diagnostic accuracy in the current literature. 6. The hyper-acute window (<2 hours from symptom onset) was identified as a priority unstudied interval, and normalization variability (absence of absolute quantification standards) was flagged as a principal source of inter-laboratory heterogeneity.
Practice implications
Circulating miR-208 should not yet be adopted as a standalone clinical diagnostic tool given substantial methodological heterogeneity, publication bias, and reduced specificity in real-world mixed chest pain populations; clinicians should interpret existing commercial or research assay results with caution outside of controlled study settings. Future translational efforts should preferentially enroll phenotypically defined STEMI and NSTEMI cohorts, mandate absolute quantification methodologies to eliminate normalization variability, and evaluate miR-208 within prospective multi-marker point-of-care panels targeting the hyper-acute (<2 h) window where conventional troponin assays are least sensitive. Institutions participating in AMI biomarker research are encouraged to align study design with the proposed miAMI framework to enable cross-study comparability and accelerate regulatory-grade validation.